These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 23085431)

  • 1. Prospects and challenges for the development of new therapies for Ewing sarcoma.
    Grohar PJ; Helman LJ
    Pharmacol Ther; 2013 Feb; 137(2):216-24. PubMed ID: 23085431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
    Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
    Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
    Ordóñez JL; Amaral AT; Carcaboso AM; Herrero-Martín D; del Carmen García-Macías M; Sevillano V; Alonso D; Pascual-Pasto G; San-Segundo L; Vila-Ubach M; Rodrigues T; Fraile S; Teodosio C; Mayo-Iscar A; Aracil M; Galmarini CM; Tirado OM; Mora J; de Álava E
    Oncotarget; 2015 Aug; 6(22):18875-90. PubMed ID: 26056084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
    Grohar PJ; Griffin LB; Yeung C; Chen QR; Pommier Y; Khanna C; Khan J; Helman LJ
    Neoplasia; 2011 Feb; 13(2):145-53. PubMed ID: 21403840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the EWS-FLI1 transcription factor in Ewing sarcoma.
    Tancredi R; Zambelli A; DaPrada GA; Fregoni V; Pavesi L; Riccardi A; Burdach S; Grohar PJ; D'Incalci M
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1317-20. PubMed ID: 25809543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.
    Vormoor B; Curtin NJ
    Curr Opin Oncol; 2014 Jul; 26(4):428-33. PubMed ID: 24840521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.
    Baruchel S; Pappo A; Krailo M; Baker KS; Wu B; Villaluna D; Lee-Scott M; Adamson PC; Blaney SM
    Eur J Cancer; 2012 Mar; 48(4):579-85. PubMed ID: 22088484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation profiling opens a new phase in the search of targeted therapy against Ewing sarcoma.
    Rello-Varona S; Tirado OM
    Pharmacogenomics; 2017 Sep; 18(14):1307-1309. PubMed ID: 28832268
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
    Kovar H
    Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.
    Amaral AT; Garofalo C; Frapolli R; Manara MC; Mancarella C; Uboldi S; Di Giandomenico S; Ordóñez JL; Sevillano V; Malaguarnera R; Picci P; Hassan AB; De Alava E; D'Incalci M; Scotlandi K
    Clin Cancer Res; 2015 Mar; 21(6):1373-82. PubMed ID: 25609059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational therapies for Ewing sarcoma: a search without a clear finding.
    Vornicova O; Bar-Sela G
    Expert Opin Investig Drugs; 2016 Jun; 25(6):679-86. PubMed ID: 26988130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapies for advanced Ewing sarcoma family of tumors.
    Jiang Y; Ludwig J; Janku F
    Cancer Treat Rev; 2015 May; 41(5):391-400. PubMed ID: 25869102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New strategies in ewing sarcoma: lost in translation?
    Arnaldez FI; Helman LJ
    Clin Cancer Res; 2014 Jun; 20(12):3050-6. PubMed ID: 24756371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
    Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Menin regulates the serine biosynthetic pathway in Ewing sarcoma.
    Svoboda LK; Teh SSK; Sud S; Kerk S; Zebolsky A; Treichel S; Thomas D; Halbrook CJ; Lee HJ; Kremer D; Zhang L; Klossowski S; Bankhead AR; Magnuson B; Ljungman M; Cierpicki T; Grembecka J; Lyssiotis CA; Lawlor ER
    J Pathol; 2018 Jul; 245(3):324-336. PubMed ID: 29672864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
    Theisen ER; Pishas KI; Saund RS; Lessnick SL
    Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.
    Harlow ML; Maloney N; Roland J; Guillen Navarro MJ; Easton MK; Kitchen-Goosen SM; Boguslawski EA; Madaj ZB; Johnson BK; Bowman MJ; D'Incalci M; Winn ME; Turner L; Hostetter G; Galmarini CM; Aviles PM; Grohar PJ
    Cancer Res; 2016 Nov; 76(22):6657-6668. PubMed ID: 27697767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.